Subject (disease extent) | 0 weeks | Â | Â | Â | 6 weeks | Â | Â | 12 weeks | Â | Â |
---|---|---|---|---|---|---|---|---|---|---|
 | Measured sites | Mean SUVmax (range) | Baseline PSA (ng/ml) | Baseline ALP (U/L) | SUV (range) [% of baseline] | PSA [% of baseline] | ALP [% of baseline] | SUV (range) [% of baseline] | PSA [% of baseline] | ALP [% of baseline] |
A (6-20 metastases) | C6, T6, L Sacrum, R ilium, L femur | 46.4 (33.1-75.3) | 370 | 118 | 31.3 (26.5-40.5) [67.5%] | 210 [56.8%] | 47 [39.8%] | 22.1 (16.7-28.2) [47.6%] | 207 [55.9%] | 53 [44.9%] |
B (superscan) | C3, L1, L5, L femur, R tibia | 15.0 (13.2-17.2) | 508 | 761 | 16.0 (11.9-21.1) [106.7%] | 459 [90.4%] | 332 [43.6%] | 3.7 (2.9-4.8) [24.7%] | 350 [68.9%] | 225 [29.6%] |
C (6-20 metastases) | L1, L3, L5, sternum, R ischium | 74.6 (54.7-98) | 78 | 129 | 66.7 (51.3-76.7) [89.4%] | 92 [117.9%] | 85 [65.9%] | 38.2 (26.5-46.9) [51.2%] | 57 [73.1%] | 70 [54.3%] |
D (>20 metastases) | Skull, L scapula, T11, L3, L ilium | 27.5 (20.3-35.4) | 551 | 89 | 25.3 (20.6-29.5) [92%] | 674 [122.3%] | 53 [59.6%] | 30.7 (21.1-59.4) [111.6%] | 607 [110.2%] | 50 [56.2%] |
E (superscan) | Skull, T12, L3, R ilium, R femur | 22.3 (11.4-28.6) | 254 | 393 | 20.3 (11-25) [91%] | 273 [107.5%] | 406 [103.3%] | 18.8 (9.8-24.8) [84.3%] | 298 [117.3%] | 290 [73.8%] |